Industry Wire 209

September 11, 2024 Jake Fishman 0 min read
  1. MGB unveils unified cancer care strategy.
  2. Apple adds sleep apnea to Apple Watch, hearing aid to AirPods Pro.
  3. NYU Langone performs first fully robotic lung transplant. 
  4. Over 1k U.S. counties have no birthing facilities or obstetricians.
  5. Allegheny Health serves as backdrop for TV drama, The Pitt.
  6. UVA faculty demands removal of CEO and dean, leaders push back.
  7. Researchers propose replacing BMI with body roundness index.
  8. One-fifth of COVID deaths attributed to strained hospital caseloads.
  9. Modesto’s Stanislaus Surgical Hospital to close after Medicare removal.
  10. Nearly 50M people have been insured through the ACA exchanges.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals February 16, 2026

DAPT Drugs Matter to Diabetics with Multivessel CAD February 16, 2026

The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that ticagrelor isn’t equivalent to prasugrel in this complex patient group. The TUXEDO-2 trial enrolled 1.8k participants across 66 clinical sites in India and randomized patients undergoing PCI to […]

Artificial Intelligence February 12, 2026

Google’s AMIE Shows Promise for Cardiology Care February 12, 2026

AI scribes and LLMs’ potential impact on cardiology just became a lot clearer after a Stanford RCT published in Nature Medicine demonstrated that Google’s AMIE system helped general cardiologists better diagnose and plan treatment for rare heart conditions. Researchers enrolled nine general cardiologists to evaluate 107 patients with suspected genetic cardiovascular disease. Each case was […]

Cardiology Pharmaceuticals February 9, 2026

Statin Side Effects Might Not be So Bad February 9, 2026

New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 the drugs’ package-listed adverse effects lack reliable evidence. In an attempt to clear statins’ name, researchers analyzed data from 19 large RCTs to distinguish real statin-associated risks from […]